Around the same time, the prototype of the Squibb logo was designed. The logo represented product uniformity, purity, efficacy and reliability based on research. By 1924, Bristol-Myers' gross ...

Summit Therapeutics Inc. ("Summit," "we," or the "Company") today announced that Robert LaCaze has joined Summit Therapeutics as Chief Commercial Officer, reporting to Manmeet S. Soni, Chief Operating ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

Bullish option flow detected in Bristol Myers ( BMY) Squibb with 11,821 calls trading, 2x expected, and implied vol increasing almost 2 points to 27.82%. May-25 67.5 calls and Mar-25 60 calls are the ...

Bristol Myers Squibb Co. closed 5.27% below its 52-week high of $63.33, which the company reached on March 11th.

This was the stock's second consecutive day of losses.

The most recent trading session ended with Bristol Myers Squibb (BMY) standing at $60.28, reflecting a +0.79% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily ...

Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last ...

Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other Friday’s worst performing stocks. Wall Street’s main indices bounced back on ...

Bristol Myers Squibb is acquiring 2seventy bio, a deal that gives the pharmaceutical giant full control over the partnered cancer cell therapy Abecma as that product faces headwinds in a ...